These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 26036708)

  • 21. Effect of diabetic macular edema on peripapillary retinal nerve fiber layer thickness profiles.
    Hwang DJ; Lee EJ; Lee SY; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2014 May; 55(7):4213-9. PubMed ID: 24833740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving strategies in the management of diabetic macular edema: clinical trials and current management.
    Thomas BJ; Shienbaum G; Boyer DS; Flynn HW
    Can J Ophthalmol; 2013 Feb; 48(1):22-30. PubMed ID: 23419295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetic Macular Edema: Options for Adjunct Therapy.
    Calvo P; Abadia B; Ferreras A; Ruiz-Moreno O; Verdes G; Pablo LE
    Drugs; 2015 Sep; 75(13):1461-9. PubMed ID: 26242766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema.
    Moshfeghi DM; Kaiser PK; Michels S; Midena E; Kitchens JW; Prenner JL; Regillo CD; Reichel E
    Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6 Suppl):S4-S14. PubMed ID: 27348433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on current pharmacologic therapies for diabetic retinopathy.
    Muns SM; Villegas VM; Flynn HW; Schwartz SG
    Expert Opin Pharmacother; 2023; 24(14):1577-1593. PubMed ID: 37431888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab for diabetic retinopathy.
    Arevalo JF; Garcia-Amaris RA
    Curr Diabetes Rev; 2009 Feb; 5(1):39-46. PubMed ID: 19199897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [From scientific evidence to clinical practice: treatment protocols for diabetic macular edema].
    López-Gálvez MI; García-Campos JM
    Arch Soc Esp Oftalmol; 2012 Dec; 87 Suppl 1():38-45. PubMed ID: 24278988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal Aflibercept in Diabetic Macular Edema: Long-Term Outcomes.
    Introini U; Casalino G
    Dev Ophthalmol; 2017; 60():71-77. PubMed ID: 28427067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
    Emerson MV; Lauer AK
    BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-VEGF therapeutic approaches for diabetic macular edema.
    Khurana RN; Do DV; Nguyen QD
    Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
    [No Abstract]   [Full Text] [Related]  

  • 33. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
    Mitchell P; Bressler N; Tolley K; Gallagher M; Petrillo J; Ferreira A; Wood R; Bandello F;
    JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
    Ollendorf DA; Colby JA; Pearson SD
    Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema.
    Sohn HJ; Han DH; Kim IT; Oh IK; Kim KH; Lee DY; Nam DH
    Am J Ophthalmol; 2011 Oct; 152(4):686-94. PubMed ID: 21782151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel therapeutic targets in diabetic macular edema: Beyond VEGF.
    Urias EA; Urias GA; Monickaraj F; McGuire P; Das A
    Vision Res; 2017 Oct; 139():221-227. PubMed ID: 28993218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal Bevacizumab (Avastin(®)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture.
    Arevalo JF; Sanchez JG; Lasave AF; Wu L; Maia M; Bonafonte S; Brito M; Alezzandrini AA; Restrepo N; Berrocal MH; Saravia M; Farah ME; Fromow-Guerra J; Morales-Canton V;
    Curr Diabetes Rev; 2010 Sep; 6(5):313-22. PubMed ID: 20594160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review on Recent Trials Evaluating the Effect of Intravitreal Injections of Anti-VEGF Agents on the Macular Perfusion of Diabetic Patients with Diabetic Macular Edema.
    Elnahry AG; Abdel-Kader AA; Habib AE; Elnahry GA; Raafat KA; Elrakhawy K
    Rev Recent Clin Trials; 2020; 15(3):188-198. PubMed ID: 32427087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refractive changes after pharmacologic resolution of diabetic macular edema.
    Deák GG; Lammer J; Prager S; Mylonas G; Bolz M; Schmidt-Erfurth U;
    Ophthalmology; 2014 May; 121(5):1054-8. PubMed ID: 24439462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-VEGF for the management of diabetic macular edema.
    Stefanini FR; Badaró E; Falabella P; Koss M; Farah ME; Maia M
    J Immunol Res; 2014; 2014():632307. PubMed ID: 24741610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.